Jasmine A. Luzum

The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin‐Associated Musculoskeletal Symptoms

Rhonda M. Cooper‐DeHoff, Mikko Niemi, Laura B. Ramsey et al. · Clinical Pharmacology & Therapeutics · 2022 · 331 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

Jasmine A. Luzum, R E Pakyz, AR Elsey et al. · Clinical Pharmacology & Therapeutics · 2017 · 133 citations · Full text

Medicine, Pharmacology, Pharmacogenetics +14

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre et al. · Pharmacogenetics and Genomics · 2014 · 51 citations · Full text

Veterinary Medicine, Pharmacokinetics, Pharmacology +14

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure

David E. Lanfear, Jasmine A. Luzum, Ruicong She et al. · Circulation Heart Failure · 2020 · 43 citations · Full text

Medicine, Cardiology, Pharmacology +17

Physicians’ Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Jasmine A. Luzum, Matthew Luzum · Personalized Medicine · 2016 · 38 citations · Full text

Medicine, Medical Education, Pharmacology +10